Who makes bucain + fentanyl?

bucain + fentanyl is developed by University of Debrecen.

What development phase is bucain + fentanyl in?

bucain + fentanyl is FDA-approved (marketed).

What are the side effects of bucain + fentanyl?

Common side effects include Respiratory depression, Hypotension, Nausea, Dizziness, Local site reactions.

Last reviewed 2026-04-22 · How we verify

bucain + fentanyl

University of Debrecen · FDA-approved active Small molecule

Bucain is a local anesthetic that blocks sodium channels, while fentanyl is an opioid agonist that binds mu receptors; together they provide combined local anesthesia and systemic analgesia.

Bucain is a local anesthetic that blocks sodium channels, while fentanyl is an opioid agonist that binds mu receptors; together they provide combined local anesthesia and systemic analgesia. Used for Local anesthesia with systemic analgesia for surgical and procedural pain management.

At a glance

Generic name	bucain + fentanyl
Sponsor	University of Debrecen
Drug class	Local anesthetic + opioid analgesic combination
Target	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
Modality	Small molecule
Therapeutic area	Pain Management / Anesthesia
Phase	FDA-approved

Mechanism of action

Bucain works by inhibiting sodium influx in nerve fibers, preventing action potential propagation and blocking pain signal transmission at the site of administration. Fentanyl acts as a mu-opioid receptor agonist in the central nervous system, enhancing pain relief through opioid pathways. This combination provides both local and systemic analgesia for pain management.

Approved indications

Local anesthesia with systemic analgesia for surgical and procedural pain management

Common side effects

Respiratory depression
Hypotension
Nausea
Dizziness
Local site reactions

Key clinical trials

Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

bucain + fentanyl CI brief — competitive landscape report
bucain + fentanyl updates RSS · CI watch RSS
University of Debrecen portfolio CI